A clinical study reportedly showed AstraZeneca's new blood thinner is more effective than Plavix, the current standard treatment among anti-platelet drugs sold by Sanofi-Aventis and Bristol-Myers Squibb. AstraZeneca previously has said it hopes the new drug, AZD6140, will be used to help prevent heart attacks and strokes in patients with acute coronary syndromes.

Full Story:

Related Summaries